SynthesisBMC cancer2025

MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis.

Defeng Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.